At a glance
ClinicalIndex Comparison Record- ✓Age at least 20 years
- ✓Histologically or cytologically confirmed non-small cell lung cancer
- ✓Activating EGFR mutation (exon 19 deletion or L858R)
- ✓Stage IV metastatic NSCLC at initial diagnosis
- ✕Progressive disease during first-line osimertinib-chemotherapy
- ✕Extensive, unresectable metastatic disease not amenable to local therapy
- ✕Untreated or clinically unstable brain metastases
- ✕Known contraindications to surgery or radiotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Cohort Observational Study of Local Therapy for the Primary Tumor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer Following Osimertinib Plus Chemotherapy (FLAURA2 Regimen)
In Brief
A Phase 2 clinical trial evaluating Local Therapy (Surgery or Radiotherapy) for Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor. Currently recruiting, targeting 70 participants across 1 site.
Detailed Summary
This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.
Study Details
Timeline
Interventions
Patients will receive local therapy, either surgical resection or radiotherapy, to the primary lung tumor following disease control after first-line treatment with osimertinib plus platinum-based chemotherapy (FLAURA2 regimen). The specific modality (surgery or radiotherapy) will be determined based on tumor characteristics, patient condition, and multidisciplinary team assessment.